

# Scioto Biosciences: Microbiome delivery platform for Activated Bacterial Therapeutics (Phase 1b Complete)




## EXECUTIVE SUMMARY

Scioto Biosciences is a clinical stage biotech company dedicated to innovative research and discovery, and development in the field of microbiome therapeutics. The Company's solution is focused on the activation of beneficial bacteria that have the potential to advance treatment for various diseases including those associated with the central nervous system and gastrointestinal tract. Scioto's lead asset, SB-121, stimulates neuroendocrine signaling, at least in part, by increased oxytocin levels. The company recently completed a double-blind, placebo-controlled Phase 1b Clinical Trial with 28-day dosing in patients with Autistic Spectrum Disorder (ASD). The study showed that SB-121 was safe and well-tolerated and demonstrated treatment-related improvements measured by the Vineland-3 Adaptive Behavior Composite Score and individual domains. The Vineland-3 data were further supported by improvements in objective eye-tracking measurements monitoring social viewing preferences.

## KEY COMPANY HIGHLIGHTS

- Experienced leadership and advisors
- Platform strategy to develop next-generation microbiome therapeutics
- Successful Phase 1b study completed (Q1 2022) in patients with ASD
- Additional indications in pipeline (C-Difficile colitis, feeding intolerance/necrotizing enterocolitis)
- Raised >\$16M in equity financing and ~\$3M in Grants from the NIH
- Key strategic partnership with Genome and Co (S. Korea KOSDAQ KS: 314130)
- **Seeking Series C investment of \$25M to support Phase II study in Autism and further develop the ABT Platform**



Therapeutic bacteria assembles in microparticle for prebiotic load



Biofilm formation ready for delivery into GI



Activated Biofilm is distributed throughout the GI system



## OPPORTUNITY

In 2021, the CDC reported that 1 in 44 children were diagnosed with Autism. Many adults and their caregivers continue to deal with the disorder. All drugs approved or prescribed off-label have undesirable side effects that significantly discourage their use. **The efficacy and safety profile of SB-121 will make it a 'first option' to patients and their caregivers when faced with the challenge of treating the disorder creating the first blockbuster opportunity in the space.**

## Contact:

Joe Trebley, CEO: [joe@sciotobiosciences.com](mailto:joe@sciotobiosciences.com)

Jim Schulz, CFO: [jim@sciotobiosciences.com](mailto:jim@sciotobiosciences.com)

9800 Crosspoint Blvd Suite 200, Fishers, IN 46256

